Prevention of Metabolic Syndrome with Yoga - A Mini Review

Abstract

ABSTRACT

Metabolic Syndrome is a mixture of complications such as cardiovascular risk, Diabetes, Stroke. Any of these complications may affect the life of the person. Yoga can maintain the physical health, mental health and spiritual health too. Several studies proved that regular practice of yoga has many beneficial effects. This review mainly focuses how metabolic syndrome (a cluster of complications) can be prevented by yoga.

Keywords

Yoga, Metabolic syndrome, Cardiovascular risk, Diabetes.

Introduction

Metabolic syndrome (Mets) is not an illness in itself. Rather, it's a gathering of danger elements - hypertension, high glucose, higher cholesterol levels, and stomach fat [1-5]. Clearly, having any of these danger components isn't serious. Be that as it may, when they're joined, they set the phase for significant issues. These complications lead to twofold danger of vein and coronary illness, which can increase heart problems and strokes [6-10].

The pathophysiology is exceptionally unpredictable and has been just somewhat illustrated. Most patients are more seasoned, large, stationary, and have a level of insulin resistance [1]. The most vital danger variables are eating regimen (especially sugarsweetened drink utilization), hereditary qualities, stress, low physical action, reduced chronobiology/rest, temperament issue/ psychotropic drug use, and extreme liquor use.

Insulin resistance (IR) is a condition in which the body's cells get to be impervious to the impacts of insulin. That is, the ordinary reaction to a given measure of insulin is diminished. Thus, more elevated amounts of insulin are required with the goal insulin should have its appropriate impacts. In this way, the pancreas repays by attempting to create more insulin. This resistance happens in light of the body's own insulin (endogenous) or when insulin is regulated by infusion (exogenous) [11-15].

Various markers of systemic irritation, including C-reactive protein, are regularly expanded, as are fibrinogen, interleukin 6, tumor necrotic factor alpha (TNF-α), and others. Some have indicated an assortment of causes, including expanded uric acid levels brought on by dietary fructose. Late research shows delayed persistent anxiety can add to metabolic disorder by disturbing the hormonal parity of the hypothalamic-pituitary-adrenal pivot (HPA-axis A useless HPA-hub causes high cortisol levels to flow, which results in raising glucose and insulin levels, which thus cause insulin-interceded impacts on fat tissue, at last advancing instinctive adiposity, insulin resistance, dyslipidemia and hypertension, with direct consequences for the bone, bringing on "low turnover" osteoporosis. HPA-hub brokenness may clarify the reported danger sign of stomach weight to cardiovascular sickness (CVD), sort type 2 diabetes and stroke. Psychosocial anxiety is additionally connected to coronary diseases [16-20].

Metabolic disorder is a danger component for neurological issue. A metabolic disorder happens when anomalous synthetic responses in the human body upset digestion system. When this happens, the patient may have a lot of a few substances, or too little of others, which are expected to stay solid. Scatters in digestion system can be acquired, in which case they are otherwise called characteristic blunders of digestive system, or they may be inherited. Numerous metabolic disorders exist; Phenylketonuria is a case of an acquired metabolic issue described by a powerlessness to separate one of the building squares of protein, the amino corrosive phenylalanine. Type I diabetes, an infection in which the pancreas does not make enough insulin to keep up adjusted glucose levels, is a metabolic issue of sugar digestion system. A case of a metabolic disorder influencing fat digestion system is Gaucher's sickness, which is characterized by an absence of the compound glucocerebrosidase. Metabolic disorders can likewise be complications of extreme illnesses or conditions, including liver or respiratory disappointment, malignancy, incessant obstructive aspiratory ailment (COPD, incorporates emphysema and endless bronchitis) and HIV/AIDS [21-25].

Metabolomics studies recommend an overabundance of natural acids, weakened lipid oxidation results, fundamental unsaturated fats and key amino acids in the blood serum of influenced patients [25]. In any case, it is not by any stretch of the imagination clear whether the collection of vital unsaturated fats and amino acids is the consequence of inordinate ingestion or abundance generation by gut micro biota.

As far as metabolic use, yoga practice is viewed as a low-level physical movement. Yoga can enhance metabolic rate, perfusion, cardiopulmonary capacity, and activity limit. Yoga is valuable in decreasing indications of MetS and can realize upgrades in lipid profiles, and circulatory strain. Yoga enhances insulin affectability and is by and large powerful in decreasing the danger of metabolic syndrome. Yoga practice is defensive against heart disappointment and atrial fibrillation, the cardiovascular diseases [26-30].

Yoga is thought to work by getting to parasympathetic pathways in the autonomic sensory system and revitalize the unwinding reaction Neuro-hormonal pathways, for example, the renin angiotensin aldosterone complex, are thought to be vital in the control of increased heart rate, increased pulse, myocardial localized necrosis, atrial fibrillation, and congestive heart disappointment [31-36]. These same neuro-hormonal pathways additionally are thought to be effective as the instruments of yoga. Because of its impact on numerous components in autonomic pathways, yoga has positive effects on reports of stress and heart rate variability. Yoga practice weakens psychological complications, advances wellbeing, and can be efficacious in self-care in the avoidance and upkeep of cardiovascular and metabolic wellbeing Various studies are conducting by utilization of yoga in preventing the metabolic syndrome [2,36-40].

Diagnosis of Metabolic Syndrome

Metabolic disorder happens when any person has three or a greater amount of the following:

•Abdominal weight (Waist perimeter of 40 inches or above in men, and 35 inches or above in ladies)

•Triglyceride level of 150 mg for every deciliter of blood (mg/dL) or more prominent

•HDL cholesterol of under 40 mg/dL in men or under 50 mg/dL in ladies

•Systolic circulatory strain (top number) of 130 m, of mercury (mmHg) or more prominent, or diastolic pulse (base number) of 85 mmHg or more prominent

•Fasting glucose of 100 mg/dL or more prominent

Metabolic disorder is accompanied by central obesity, dyslipidemia, compromised fasting glucose, and hypertension [3,41-45]. Shockingly, these components add to harm the endothelium that thus, will deduce in the advancement of different confusions saw in the metabolic disorder. Endothelial dysfunction is chiefly brought about by a diminishing in nitric oxide (NO) accessibility because of decreased NO generation and increment in oxygen-inferred free radicals (ROS) that can respond with NO and inactivates the dynamic atom [44].

Most broadly the metabolic syndrome components are atherogenic dyslipidemia, raised circulatory strain, and lifted plasma glucose. People with these qualities ordinarily show a prothrombotic state. Atherogenic dyslipidemia comprises of a total of lipoprotein variations from the group including raised serum triglyceride and Apo lipoprotein B (apoB), expanded little LDL particles, and a decreased level of HDL cholesterol (HDL-C). The metabolic disorder is regularly suggested as a discrete element with a solitary cause. The dominating hidden danger variables for the disorder have stomach obesity and insulin resistance other related conditions can be physical inactivity, aging, and hormonal imbalance [45-47]. An atherogenic diet (e.g. an eating regimen rich in soaked fat and cholesterol) can improve hazard for creating cardiovascular sickness in individuals with the disorder, in spite of the fact that this eating regimen is not recorded particularly as a fundamental danger component for the condition. Numerous metabolic pathways have additionally been proposed to connection insulin resistance and compensatory hyperinsulinemia to the next metabolic danger elements. In spite of the fact that insulin-safe people need not be clinically large, they all things considered generally have a strange fat conveyance that is portrayed by prevalent abdominal area fat [18]. Abdominal area fat corresponds with insulin resistance. Overabundance abdominal area fat can accumulate either intraperitoneally (instinctive fat) or subcutaneously. Numerous agents assert that overabundance instinctive fat is more certainly connected with insulin resistance than other fat tissue compartment [48-51].

Regardless of the relative commitments of instinctive fat and stomach subcutaneous fat to insulin resistance, an example of stomach (or abdominal area) adiposity associates all the more certainly with insulin resistance and the metabolic disorder than lowers body obesity [38]. An interesting component of abdominal area adiposity is a strangely high arrival of no esterified unsaturated fats from fat tissue this adds to amassing of lipid in locales other than fat tissue. Ectopic lipid aggregation in muscle and liver apparently leads to insulin resistance and dyslipidemia. Several late reports demonstrate that the metabolic disorder is connected with more serious danger for cardiovascular disease, yet once type 2 diabetes mellitus raises, cardiovascular danger increases even more. Finally, insulin resistance and the metabolic disorder are connected with an assortment of other conditions some of these are fatty liver, polycystic ovary syndrome, cholesterol gallstones, rest apnea, lipodystrophies and protease-inhibitor treatment for HIV [52-65].

Management of Metabolic Syndrome

The essential objective of clinical administration in people with the metabolic disorder is to decrease hazard for clinical atherosclerotic element. Indeed, even in individuals with the metabolic disorder, first-line treatment is coordinated toward the real hazard variables: LDL-C above objective, hypertension, and diabetes [6,12]. Prevention of sort 2 diabetes mellitus is another essential objective when it is not present in a man with the metabolic disorder. For some people with diabetes, hazard component administration must be strengthened to reduce their higher danger for metabolic syndrome. The primary objective for prevention of the metabolic disorder fundamentally is to relieve the modifiable, hidden danger variables (corpulence, physical activity, and atherogenic diet) through way of life changes. Lifestyle change successfully will reduce the greater part of the metabolic danger components. At that point, if danger is sufficiently high, thought can be given to consolidating drug treatment to the regimen. The need of medication treatment is rises of LDL-C, circulatory strain, and glucose; current rules for their administration to be taken after. Identifying metabolic syndrome is some portion of general risk assessment for cardiovascular infection.

Although numerous individuals might be hereditarily defenseless to the metabolic disorder, rarely does it turn out to be clinically showed without over weight and physical laziness. Thus, treatments to relieve these fundamental danger components constitute first-line component. The motivation to change hidden danger variables is to anticipate or defer onset of cardiovascular diseases and if type 2 diabetes mellitus is not officially present, a corresponding objective is to anticipate it also. Both weight reduction and maintenance of a lower weight are best accomplished by a mix of decreased caloric administration and expanded physical action and the utilization of standards of lifestyle change [66-70]. At present accessible weight reduction drugs have restricted utility in the administration of stoutness.

Increasing physical activity helps with weight reduction. It additionally has beneficial effects on metabolic risk factor. Beyond weight ability to control and decrease of aggregate calories, the eating regimen diet should be low in soaked fats, Trans fats, cholesterol, sodium, and straightforward sugars. Compelling weight reduction requires a mix of caloric confinement, physical movement, and inspiration; successful long lasting support of weight reduction basically requires a harmony between caloric admission and physical action.

Physical Activity is very essential to manage the metabolic syndrome [71-94]. Yoga helps in maintaining the body physically fit. To reduce the risk of the metabolic syndrome physical fitness is necessary. Several methods are there in yoga. Some of them are Asanas, Pranayamas, Kriyas. The Asanas which prevent the diabetes are Suryanamashkaras, Arthamatsyendrasana, Paschimoorthana, Hamsa, Mayura, Jatariparivarthana asana. Pranayamas include Suryabhedana, Chandra Bhedana, Seethli, Seetkari, Brahmari, Bastrika, Nadisodhana. As Cardiovascular risk patients’ needs utmost care. So those asanas performed for preventing diabetes should not be performed by cardiac patients. The cardiac patients should practice simple asanas like thadasana and they should avoid practice of complicated asanas and pranayamas [95-98]. They should not practice forceful pranayamas like bastrika. Nadisodhana is the best fit pranayama for cardiac patients. A detailed procedure and benefits for all these yogic techniques is provided by Yogacharya Rao [99]. Meditation and pranayama’s will help to keep the mind relaxed and improves the concentration power too [100].

Discussion

Regular practice of yoga has several beneficial effects. Several studies proved the advantages of yoga. So, Metabolic Syndrome a cluster of complications can also be prevented by regular practice of yoga. Healthy diet also plays key role in preventing these complications. This Review presented the brief note regarding metabolic syndrome and its management by alternative measures like yoga.

References

1. Durá-Travé T, et al. Leptin and metabolic syndrome in obese pediatric population: A cross-sectional study. J Obes Weight Loss Ther. 2016;6:305.
2. Suarez J and Díaz-Juárez J. Post-translational modifications of proteins in metabolic syndrome. J Metabolic Synd. 2016;5:e117.
3. Birdee GS, et al. Yoga combined with health education for risk reduction of metabolic syndrome: A randomized controlled pilot feasibility study. J Diabetes Metab.2015;6:588.
4. Mandob DE, et al. Prevalence of metabolic syndrome among mbo women yaounde-cameroon. J Metabolic Synd. 2015;4:186.
5. Giampetruzzi F and Garruti G. Any link between autonomic dysfunction and metabolic syndrome? J Metabolic Synd. 2016;5:195.
6. Aye M, et al. A Rapid, Inexpensive and noninvasive screening for metabolic syndrome, type 2 diabetes mellitus and coronary artery disease in a Malaysian population. J Metabolic Synd. 2013;2:124.
7. Hanefeld M, et al. The metabolic syndrome and cardiovascular diseases: An update of medical treatment. J Metabolic Synd 2014;3:160.
8. Mbangama MA, et al. Past medical, gynecological and pregnancy-related history and independent metabolic syndrome components among menopausal women: A hospital-based study. J Metabolic Synd. 2015;4:184.
9. Patel NKJ, et al. Metabolic syndrome and its impact on cardiovascular diseases. J Metabolic Synd. 2014;3:142.
10. Ramírez-Murillo C, et al. Prevalence of metabolic syndrome diagnosed by three different criteria in school-aged children from rural and urban areas of northwest Mexico. J Metabolic Synd. 2015;4:181.
11. Roever L and Resende ES. The cutoff values of epicardial fat in metabolic syndrome, cardiovascular risk factors, coronary and carotid stenosis. J Metabolic Synd 2015;4:e116.
12. Roever L and Borges ASR. Cardiac steatosis: Is it related to ectopic obesity, insulin sensitivity, diabetes mellitus and metabolic syndrome? J Cardiovasc Dis Diagn. 2015;3:e110.
13. Aye M. Metabolic syndrome (MetS). J Metabolic Synd. 2014;4:e112.
14. Voma C, et al. Low hepatic Mg2+ content promotes liver dysmetabolism: Implications for the metabolic syndrome. J Metabolic Synd. 2014;3:165.
15. Mogarekar MR, et al. Metabolic syndrome. J Cell Sci Ther. 2015;6:192.
16. Zhao X, et al. Prevalence of metabolic syndrome and overweight/obesity among Chinese women of childbearing age: A cross-sectional epidemic study. J Anesth Clin Res. 2014;5:444.
17. Anand CR, et al. Metabolic syndrome is associated with increased severity of diabetic retinopathy. J Metabolic Synd. 2014;3:145.
18. Hamrani A, et al. Prevalence of metabolic syndrome and its individual components among Moroccan adolescents: The role of overweight-obesity and excess body fat. J Metabolic Synd. 2013;2:129.
19. Youssef SM, et al. Remodelling metabolic syndrome components to adapt them to the Tunisian context and to determine a sole metric criterion. J Metabolic Synd. 2013;2:121.
20. Youssef SM, et al. Can metric parameter combining metabolic syndrome components usefully predict coronary artery disease? J Metabolic Synd. 2013;2:119.
21. Akl LD, et al. Factors associated with metabolic syndrome in middle-aged women with and without HIV. J Metabolic Synd. 2016;5:200.
22. Parry IA, et al. The prevalence of non-alcoholic fatty liver disease and its association with metabolic syndrome and obesity in pediatric population of north India. J Metabolic Synd 2012;1:118.
23. Bernabé J, et al. Consumption a citrus-based juice enriched with aronia melanocarpa. J Nutr Disorders Ther. 2015;5:178.
24. Brock KE, et al. Vitamin D and metabolic syndrome in immigrant East Asian women living in Sydney, Australia: A pilot. J Metabolic Synd. 2012;1:103.
25. Gauthier A, et al. The leptin to adiponectin ratio is a marker of the number of metabolic syndrome criteria in French adults. J Metabolic Synd. 2012;1:101. 
26. Ostovar R, et al. Prevalence of metabolic syndrome in hospitalized patients in two cardiology wards. J Metabolic Synd. 2012;1:108.
27. Dodson MV and Hausman GJ. Metabolic syndromes: Resolving a malady that involves numerous tissues, cells, regulators and regulatory pathways. J Metabolic Synd. 2012;1:e101.
28. Zhang J, et al. Adiponectin, resistin and leptin: Possible markers of metabolic syndrome. Endocrinol Metab Syndr. 2015;4:212.
29. Guénard F, et al. Use of blood as a surrogate model for the assessment of visceral adipose tissue methylation profiles associated with the metabolic syndrome in men. J Mol Genet Med. 2016;10:198.
30. Sharma M and Mahna R. Obesity, metabolic syndrome and physical activity in Indian adults. J Metabolic Synd. 2012;1:114.
31. Patel BS and Benavides S. Yoga for pediatric obesity. J yoga phys Therapy. 2011;1:e105.
32. Robson R. A critical assessment of the acute effects of yoga and cardiovascular exercise on markers of mood and stress. J Yoga Phys Therapy. 2011;1:105.
33. Ramos-Jiménez A, et al. Hatha yoga program determinants on cardiovascular health in physically active adult women. J Yoga Phys Therapy. 2011;1:103.
34. Majithia R and Koch TR. Our obesity crisis requires the development of new, widely available options: Can yoga function in a major role? J Yoga Phys Therapy. 2011;1:e102.
35. Johnson CC, et al. Feasibility and acceptability of an internet-based, African dance-modified yoga program for African-American women with or at risk for metabolic syndrome. J Yoga Phys Ther. 2014;4:174.
36. Naik D and Thomas N. Yoga- a potential solution for diabetes & metabolic syndrome. Indian J Med Res. 2015;141:753-756.
37. Chu P, et al. The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2016;23:291-307.
38. Innes EK, et al. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: A systematic review. J Am Board Fam Med. 2005;18:491-519.
39. Seo YD, et al. Yoga training improves metabolic parameters in obese boys. Korean J Physiol Pharmacol. 2012;16:175-180.
40. Ross A and Thomas S. The health benefits of yoga and exercise: A review of comparison studies. The Journal of Alternative and Complementary Medicine. 2010;16:3-12.
41. Sarvottam K and Yadav RK. Obesity-related inflammation & cardiovascular disease: Efficacy of a yoga-based lifestyle intervention. Indian J Med Res. 2014;139:822-834.
42. Hainsworth KR, et al. Hatha yoga for pediatric obesity: A pilot study. J Yoga Phys Ther. 2014;4:172.
43. Sagna Y, et al. Obesity and metabolic syndrome in a Burkina Faso urban area: Prevalence, associated factors and comorbidities. J Nutr Disorders Ther. 2014;4:141.
44. Halcox JPJ, et al. Coronary endothelial dysfunction, obesity and metabolic syndrome. J Diabetes Metab. 2014;5:362.
45. Shyam S, et al. Metabolic syndrome, abnormal glucose tolerance and high sensitivity- c-reactive protein among women with a history of gestational diabetes mellitus. J Diabetes Metab. 2014;5:424.
46. Deniz Dincer U. Monitoring, but this time right direction! Seeding collaborative interdisciplinary team in diabetes, metabolic syndrome and technology. J Metabolic Synd. 2013;3:e107.
47. Gliozzi M, et al. Bergamot polyphenols: Pleiotropic players in the treatment of metabolic syndrome. J Metabolic Synd. 2014;3:143.
48. Shoukri MM, et al. Statistical issues in the evaluation of clustering of metabolic syndrome in spousal pairs. J Biomet Biostat. 2015;6:233.
49. Roever L and Resende ES. Diabetes and metabolic syndrome can contribute to recurrent vascular events in patients with lacunar stroke? J Neurol Disord. 2015;S1:e101.
50. Shuto H, et al. Assessment of waist circumference index as a new screening parameter for pre-metabolic syndrome. J Health Edu Res Dev. 2015;3:139.
51. Fadoua G, et al. Leptin, insulin and lipid profiles in obese subjects with and without metabolic syndrome in the region of cap-bon: Tunisia. Endocrinol Metab Syndr. 2015;4:193.
52. Genel S, et al. Is the non-alcoholic fatty liver disease part of metabolic syndrome? J Diabetes Metab. 2015;6:526.
53. Kelli HM, et al. Cardio metabolic syndrome: A global epidemic. J Diabetes Metab. 2015;6:513.
54. Gomes TN, et al. “Fat-but-active”: does physical activity play a significant role in metabolic syndrome risk among children of different BMI categories? J Diabetes Metab. 2014;5:421.
55. Orgaz P, et al. Impact of metabolic syndrome on the quality of life of menopausal women. J en Pract. 2015;3:205.
56. Huang X, et al. Relationship between uric acid and endothelial function in hypertensive patients with metabolic syndrome. J Clin Exp Cardiolog. 2016;7:416.
57. Gierach M, et al. The correlation between ldl-c and non-hdl-c levels and cardiovascular events in patients with metabolic syndrome. Endocrinol Metab Syndr. 2016;5:229.
58. Song S, et al. Sex differences in the risk of metabolic syndrome and its diagnostic components in Korean adults. Endocrinol Metab Syndr. 2016;5:233.
59. Gierach M, et al. The correlation between ldl-c and non-hdl-c levels and cardiovascular events in patients with metabolic syndrome. Endocrinol Metab Syndr. 2016;5:229.
60. Dincer UD. Human endothelial progenitor cell application in vascular diseases seen in metabolic syndrome. J Metabolic Synd. 2015;4:e115.
61. Mahmood D. Management of residual cardiovascular risk in dyslipidaemic patient with metabolic syndrome. Gen Med (Los Angel). 2015;3:163.
62. Adamu Umar G, et al. Prevalence of metabolic syndrome according to three defining criteria in hypertensive population in a rural hospital setting. J Hypertens. 2015;4:196.
63. Khthir R and Espina FL. The metabolic syndrome in rural UAE: The effect of gender, ethnicity and the environment in its prevalence. J Metabolic Synd. 2014;3:159.
64. Hanefeld M, et al. The metabolic syndrome and cardiovascular diseases: An update of medical treatment. J metabolic synd. 2014;3:160.
65. de Piano A, et al. Nonalcoholic fatty liver disease (NAFLD), a manifestation of the metabolic syndrome: New perspectives on the nutritional therapy. Endocrinol Metab Synd. 2014;3:135.
66. Teixeira Henriques ACP, et al. Metabolic syndrome after preeclampsia: A cohort study with a mean follow up of 14 years. J Metabolic Synd. 2014;3:152.
67. Comhaire F. Nutriceutical approach to the metabolic syndrome. Endocrinol Metab Synd. 2014;3:134.
68. Tadesse FG, et al. Metabolic syndrome biomarkers in type ii diabetic Ethiopian patients. J Metabolic Synd. 2014;3:139.
69. Kanagasabai T, et al. Metabolic syndrome and prevalent any-site, prostate, breast and colon cancers in the U.S. adult population: NHANES 1999-2010. J Metabolic Synd. 2014;3:135.
70. Gruppen EG, et al. Plasma apoE is elevated in metabolic syndrome: Importance of large very low density and low density lipoprotein particles. J Mol Biomark Diagn. 2015;6:210.
71. Cajka V. Dissertation: Effectiveness of yoga exercises in prevention and treatment of metabolic syndrome 2015.
72. Cohen BE, et al. Restorative yoga in adults with metabolic syndrome: A randomized, controlled pilot trial. Metab Syndr Relat Disord. 2008;6:223-229.
73. Yadav RK, et al. Efficacy of a short-term yoga-based lifestyle intervention in reducing stress and inflammation: preliminary results. The Journal of Alternative and Complementary Medicine. 2012;18:662-667.
74. Seo YD, et al. Yoga training improves metabolic parameters in obese boys. Korean J Physiol Pharmacol. 2012;16:175-180.
75. Ross A and Thomas S. The health benefits of yoga and exercise: A review of comparison studies. The Journal of Alternative and Complementary Medicine. 2010;16:3-12.
76. Hartley L, et al. Yoga for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2014.
77. Hagins M, et al. Effectiveness of yoga for hypertension: Systematic review and meta-analysis. Evid Based Complement Alternat Med. 2013;649836.
78. Siu PM, et al. Effects of 1 year yoga on cardiovascular risk factors in middle-aged and older adults with metabolic syndrome: A randomized trial. Diabetol Metab Syndr. 2015;7:40.
79. Sharma M and Knowlden AP. Role of yoga in preventing and controlling type 2 diabetes mellitus. J Evid Based Complementary Altern Med. 2012;17:88-95.
80. Jimenez AR, et al. Cardiovascular and metabolic effects of intensive hatha yoga training in middle-aged and older women from northern Mexico. Int J Yoga. 2009;2:49-54.
81. Sarvottam K, et al. Adiponectin, interleukin-6, and cardiovascular disease risk factors are modified by a short-term yoga-based lifestyle intervention in overweight and obese men. The Journal of Alternative and Complementary Medicine. 2013;19:397-402.
82. McDermott KA, et al. A yoga intervention for type 2 diabetes risk reduction: A pilot randomized controlled trial. BMC Complement Altern Med. 2014;14:212.
83. Manchanda SC and Madan K. Yoga and meditation in cardiovascular disease. Clinical Research in Cardiology. 2014;103:675-680.
84. Yang K, et al. Utilization of 3 month yoga program for adults at high risk for type 2 diabetes: A pilot study. Evid Based Complement Alternat Med. 2011;257891.
85. Kwong JS, et al. Yoga for secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2015;1.
86. Cade WT, et al. Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors. HIV Med. 2010;11:379-388.
87. Yeung A, et al. Yoga and cardiac rehabilitation – a brief review of evidence. J Yoga Phys Ther. 2015;5:207.
88. Groessl EJ. An overview of yoga research for health and well-being. J Yoga Phys Ther 2015;5:210.
89. Tay K and Baldwin AL. Effects of breathing practice in vinyasa yoga on heart rate variability in university students- a pilot study. J Yoga Phys Ther. 2015;5:214.
90. Dada R, et al. Yoga and meditation as a therapeutic intervention in oxidative stress and oxidative DNA damage to paternal genome. J Yoga Phys Ther. 2015;5:217.
91. Mullur RS and Ames D. Impact of a 10 min seated yoga practice in the management of diabetes. J Yoga Phys Ther. 2016;6:224.
92. Joshua S and Dunbar CC. Cardiovascular and metabolic responses to vinyasa yoga and paced surya namaskar. J Yoga Phys Ther. 2016;6:230.
93. Mondal S, et al. Blood sugar and lipid profile adaptations to yoga therapy. J Yoga Phys Ther. 2014;4:175.
94. Manchanda SC, et al. Reversal of early atherosclerosis in metabolic syndrome by yoga – a randomized controlled trial. J Yoga Phys Ther. 2013;3:132.
95. Bhavanani AB, et al. Suryanadi pranayama (right unilateral nostril breathing) may be safe for hypertensives. J Yoga Phys Ther. 2012;2:118.
96. Omkar SN. Surya namaskaar for holistic wellbeing: a comprehensive review of surya namaskaar. J Yoga Phys Ther. 2012;2:e109.
97. Jain G, et al. Effect of bhramari pranayama on volunteers having cardiovascular hyper-reactivity to cold pressor test. J Yoga Phys Therapy. 2011;1:102.
98. Dvivedi J, et al. A study of the effects of training of 61-point relaxation in women suffering from stress of premenstrual syndrome. J Yoga Phys Therapy. 2011;1:106.
99. Rao RR. Yoga chaitanya pradeepika. Yoga chaitanya ramam, Viginigiri, India. 2003.
100. Harinath K, et al. Effects of hatha yoga and omkar meditation on cardiorespiratory performance, psychologic profile and melatonin secretion. The Journal of Alternative and Complementary Medicine. 2004;10:261-268.